Embryolethality and teratogenicity of butyl benzyl phthalate in rats

Exposure to benzyl butyl phthalate (BBP) leads to increased double-strand break formation and germline dysfunction in Caenorhabditis elegans

Benzyl butyl phthalate (BBP), a plasticizer found in a wide range of consumer products including vinyl flooring, carpet backing, food packaging, personal care products, and children's toys, is an endocrine-disrupting chemical linked to impaired reproduction and development in humans. Despite evidence that BBP exposure perturbs the integrity of male and female gametes, its direct effect on early meiotic events is understudied. Here, using the nematode Caenorhabditis elegans, we show that BBP exposure elicits a non-monotonic dose response on the rate of X-chromosome nondisjunction measured using a high-throughput screening platform. From among the range of doses tested (1, 10, 100 and 500 μM BBP), we found that 10 μM BBP elicited the strongest effect on the germline, resulting in increased germ cell apoptosis and chromosome organization defects. Mass spectrometry analysis shows that C. elegans efficiently metabolizes BBP into its primary metabolites, monobutyl phthalate (MBP) and monobenzyl phthalate (MBzP), and that the levels of BBP, MBP, and MBzP detected in the worm are within the range detected in human biological samples. Exposure to 10 μM BBP leads to germlines with enlarged mitotic nuclei, altered meiotic progression, activation of a p53/CEP-1-dependent DNA damage checkpoint, increased double-strand break levels throughout the germline, chromosome morphology defects in oocytes at diakinesis, and increased oxidative stress. RNA sequencing analysis indicates that BBP exposure results in the altered expression of genes involved in xenobiotic metabolic processes, extracellular matrix organization, oocyte morphogenesis, meiotic cell cycle, and oxidoreduction. Taken together, we propose that C. elegans exposure to BBP leads to increased oxidative stress and double-strand break formation, thereby compromising germline genomic integrity and chromosome segregation.

Bone Disruption and Environmental Pollutants

BACKGROUND

Endocrine Disrupting Chemicals (EDCs) are ubiquitous and may significantly contribute in environmental pollution, thus contaminating humans and wildlife. Environmental pollutants could interfere with bone homeostasis by means of different mechanisms, which include hormonal imbalance, direct osteoblasts toxicity and enanchment of osteoclasts activity, thus leading to osteopenia or osteoporosis. Among these, bisphenols, dioxins, polycyclic aromatic hydrocarbons, polychlorobiphenyls, poly- and perfluoroalkyls, phthalates, parabens, organotins and cadmium may play a role in bone distuption.

METHODS

PubMed/MEDLINE, ISI-web of knowledge and Google scholar databases were searched for medical subject headings terms and free-text word related to the aforementioned classes of chemicals and bone metabolism and remodelling for better clarifying and understanding the main mechanisms of bone disruption.

RESULTS

Several of EDCs act as xenoestrogens. Considering that estrogens play a significant role in regulating bone remodeling, most of these chemicals generate hormonal imbalance with possible detrimental consequences on bone tissue structure and its mechanical and non-mechanical properties.

DISCUSSION

A lot of evidences about bone distruptors came from in vitro studies or animal models, and conduct to equivocal results. In addition, a few data derived form humans and most of these data focused on the impact of EDCs on bone mineral density without considering their influence on long-term fracture risk. Moreover, it should be taken into account that humans are exposed to a mixture of EDCs and the final effect on bone metabolism might be the result of either a synergism or antagonist effects among them. Age of first exposure, cumulative dose exposure over time, and the usually observed non-monotonic dose-response curve for EDCs should be considered as other important variable influencing the final effect on bone metabolism.

CONCLUSION

Taking into account these variables, observational studies are needed to better analyze this issue both for echological purpose and to preserve bone health.

Assessment of the impact of genetically modified LibertyLink® maize on reproductive function and progeny development of Wistar rats in three generations

This publication presents the assessment of the impact of genetically modified (GM) LibertyLink® maize on reproductive function, prenatal and postnatal progeny development of Wistar rats over three generations. The animals were divided into two groups, which were fed with rodent diet with inclusion of GM LibertyLink® ('test' group) and non-GM near-isogenic counterpart ('control' group) maize varieties. The maize was included into the diet at maximum possible level (between 32 and 33%) not causing nutritional imbalance or metabolic disturbance for the experimental animals. Data analysis showed no impact of LibertyLink® maize on the animals' fertility: the observed mating efficiency in both groups was within the normal expected range values under the given experiment conditions. The comparison of progeny prenatal development in the generations F0-F2 has not shown any differences between the groups. Analysis of the physical development of the F0-F2 progeny or pups body weight and length progress did not show any abnormalities. The average number of pups per litter in the control and test groups was within the expected range of variations. Therefore, the results should be considered as direct evidence of the lack of any reproductive toxicity of LibertyLink® maize (a.k.a. T25 maize).

Endocrine disruptors and bone metabolism

Bone microenvironment is a complex dynamic equilibrium between osteoclasts and osteoblasts and is modulated by a wide variety of hormones and osteocyte mediators secreted in response to physiological and pathological conditions. The rate of remodeling involves tight coupling and regulation of both cells population and is regulated by a wide variety of hormones and mediators such as parathyroid hormone, prostaglandins, thyroid hormone, sex steroids, etc. It is also well documented that bone formation is easily influenced by the exposure of osteoblasts and osteoclasts to chemical compounds. Currently, humans and wildlife animals are exposed to various environmental xenoestrogens typically at low doses. These compounds, known as endocrine disruptor chemicals (EDCs), can alter the systemic hormonal regulation of the bone remodeling process and the skeletal formation. This review highlights the effects of the EDCs on mammalian bone turnover and development providing a macro and molecular view of their action.

Use of the rat postimplantation embryo culture to assess the embryotoxic potency within a chemical category and to identify toxic metabolites

The implementation of in vitro alternatives in the safety evaluation of chemicals in the animal intensive area of reproductive toxicity testing is highly desirable, but has been limited by issues around predictivity and applicability domains. The validation of alternatives may gain from a category approach, in which, rather than validating a test for the universe of chemicals, its predictive value is assessed for each class of chemicals for which the test represents relevant end point(s). We studied the embryotoxicity in rodent postimplantation whole embryo culture (WEC) of a series of phthalates and their metabolites. Phthalate diesters are widely applied industrial chemicals, their monoester derivatives being considered as their embryotoxic metabolites. The relative in vitro potency of three out of four monophthalates was found to mimick that of corresponding diphthalates tested in vivo. The phthalate that deviated from this ranking, monoethylhexylphthalate (MEHP), showed a relatively high in vitro toxicity as compared to in vivo data. This deviation could be explained through kinetic differences among phthalates, as shown between MEHP and monobutylphthalate. In addition, in vitro testing of specific secondary MEHP metabolites showed that they were all less potent than MEHP. This finding confirmed that MEHP in vitro embryotoxicity is most likely the best correlate to DEHP in vivo embryotoxicity. This study shows that a category approach in the assessment of the validation of in vitro alternatives is feasible, and can be improved when kinetic considerations are taken into account.

Benzyl butyl phthalate influences actin distribution and cell proliferation in rat Py1a osteoblasts

We previously reported that transient administration of phthalates induced actin cytoskeleton disruption in Py1a osteoblasts. However, the mechanism of this transient effect was not elucidated. In this study we provided evidence that the actin cytoskeletal re-established conditions are dependent on new actin expression and synthesis. To assess the role of phthalates in modulating the distribution of actin, confocal and electron microscopy studies were carried out. Results indicated a modification of actin distribution after phthalate administration. In addition, a relation with the nucleoskeletal component lamin A supports the hypothesis that phthalates may participate in regulatory cell processes involving actin in Py1a osteoblasts. The present study also supports the mitogenic effects of phthalates, which involve microfilament disruption, nuclear actin and lamin A. In particular, the increased levels of cyclin D3, which in mammalian cells plays a critical role in G1 to S transition and is a putative proto-oncogene in benzyl butyl phthalate treated cells, suggested a possible effect of the endocrine disruptor in cancer processes.

Toxicological characteristics of endocrine-disrupting chemicals: developmental toxicity, carcinogenicity, and mutagenicity

It is generally accepted that endocrine-disrupting chemicals (EDCs) play a role in a variety of adverse health effects in an intact organism or its progeny as a consequence of changes in the endocrine system. Primary toxic effects of EDCs were reported to be related to infertility, reduction in sperm count, and teratogenicity, but other important toxic effects of EDCs such as carcinogenicity and mutagenicity have also been demonstrated. The aim of the present study was to systematically analyze the toxicological characteristics of EDCs in pesticides, industrial chemicals, and metals. A comprehensive literature survey on the 48 EDCs classified by the Centers for Disease Control and Prevention (CDC) was conducted using a number of databases which included Medline, Toxline, and Toxnet. The survey results revealed that toxicological characteristics of EDCs were shown to produce developmental toxicity (81%), carcinogenicity (79%, when positive in at least one animal species; 48%, when classified based on IARC evaluation), mutagenicity (79%), immunotoxicity (52%), and neurotoxicity (50%). Regarding the hormone-modulating effects of the 48 EDCs, estrogenic effects were the most predominant in pesticides, while effects on thyroid hormone were found for heavy metals. EDCs showing estrogen-modulating effects were closely related to carcinogenicity or mutagenicity with a high degree of sensitivity. Systematic information on the toxicological characteristics of the EDCs will be useful for future research directions on EDCs, the development of new screening methods, legal regulation, and for investigations of their mechanism of action.

Metabolism of butyl benzyl phthalate by Gordonia sp. strain MTCC 4818

The microbial degradative characteristics of butyl benzyl phthalate (BBP) were investigated by the Gordonia sp. strain MTCC 4818 isolated from creosote-contaminated soil. The test organism can utilize a number of phthalate esters as sole sources of carbon and energy, where BBP was totally degraded within 4 days under shake culture conditions. High performance liquid chromatography profile of the metabolites isolated from spent culture indicated the accumulation of two major products apart from phthalic acid (PA), which were characterized by gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy as mono-n-butyl phthalate (MBuP) and monobenzyl phthalate (MBzP). Neither of the metabolites, MBuP, MBzP or PA, supported growth of the test organism, while in resting cell transformation, the monoesters were hydrolyzed to PA to a very minor extent, which was found to be a dead-end product in the degradation process. On the other hand, the test organism grew well on benzyl alcohol and butanol, the hydrolyzed products of BBP. The esterase(s) was found to be inducible in nature and can hydrolyze in vitro the seven different phthalate diesters tested to their corresponding monoesters irrespective of their support to the growth of the test organism.

Metabolism of n-butyl benzyl phthalate in the female Wistar rat. Identification of new metabolites

n-Butyl benzyl phthalate (BBP), a plasticizer used in polyvinylchloride (PVC) and other polymers, has been orally administered to female Wistar rats with four doses (150, 475, 780 and 1500 mg/kg body weight/day) for 3 consecutive days. Metabolites recovered in urines were analysed by gas chromatography-mass spectrometry (GC-MS) after 24, 48 and 72 hours. Six metabolites were identified. Mono-n-butyl phthalate (MBuP) and mono-n-benzyl phthalate (MBeP) represented respectively 29-34% and 7-12% of the total recovered metabolites. Hippuric acid, the main metabolite of benzoic acid, represented the second major metabolite (51-56%). Phthalic acid, benzoic acid and an omega-oxidized metabolite of MBuP were also recovered in urine but in small quantities. BBP was never identified in urines. Total urinary metabolites recovery represented 56% of the dose administered in the first 24 hours. However, total recovery decreased when the dose increases (43% at 780 mg/kg body weight/day, only 30% at 1500 mg/kg body weight/day). Whatever the time was, BBP metabolites recovered in urines were all present and in the same proportions for the two lowest doses. Discrepancy in metabolites quantities expressed as percentages of the dose observed in urine of rat treated with the highest BBP dose disappeared with time as MBuP, MBeP and hippuric acid recovery has significantly increased at day 3. Metabolic profile of BBP in female rats has been established. The aim of the present study is to identify further the active(s) agent(s) involved in the BBP malformations and teratogenic effects.

Reproductive effects of butyl benzyl phthalate in pregnant and pseudopregnant rats

In our previous studies, butyl benzyl phthalate (BBP) was found to be embryolethal and teratogenic in rats. In this study, the reproductive effects of BBP were investigated in pregnant and pseudopregnant rats. Rats were given BBP by gastric intubation at 0, 250, 500, 750, or 1000 mg/kg on Days 0 to 8 of pregnancy and the pregnancy outcome was determined on Day 20 of pregnancy. The same doses of BBP were given to pseudopregnant rats, with an induced decidual cell response on Days 0 to 8 of pseudopregnancy, and the uterine weight on Day 9 served as an index of the uterine decidualization. BBP caused significant increases in the incidences of preimplantation loss in females successfully mated at 1000 mg/kg and of postimplantation loss in females having implantations at 750 mg/kg and above. Uterine decidual growth in pseudopregnant rats was significantly decreased at 750 mg/kg and above. These findings suggest that early embryonic loss due to BBP may be mediated, at least in part, via the suppression of uterine decidualization, an impairment of uterine function.

Characterization of developmental toxicity of mono-n-benzyl phthalate in rats

The objective of this study was to characterize the developmental toxicity of mono-n-benzyl phthalate (MBeP), which is one of the major metabolites of n-butyl benzyl phthalate. Pregnant rats were given MBeP by gastric intubation at 250, 375, 500, or 625 mg/kg on days 7 to 9, 10 to 12, or 13 to 15 of pregnancy. A significantly increased incidence of postimplantation loss was found at 500 mg/kg and above regardless of the days of administration. While administration of MBeP on days 7 to 9 or 13 to 15 at 375 mg/kg and above was significantly teratogenic, no evidence of teratogenicity was detected when MBeP was given on days 10 to 12. Deformity of the vertebral column and ribs and dilation of the renal pelvis were frequently observed after administration on days 7 to 9. Cleft palate and fused sternebrae were exclusively found after administration on days 13 to 15. These findings indicate that the susceptibility and spectrum of the developmental toxicity of MBeP vary with the developmental stages at the time of administration.

Phase specificity of developmental toxicity after oral administration of mono-n-butyl phthalate in rats

The objective of this study was to further characterize the developmental toxicity of mono-n-butyl phthalate (MBuP), which is one of the major metabolites of n-butyl benzyl phthalate (BBP) and di-n-butyl phthalate (DBP). Pregnant rats were given MBuP by gastric intubation at a dose of 500, 625 or 750 mg/kg on days 7-9, days 10-12, or days 13-15 of pregnancy. A significantly increased incidence of postimplantation loss was noted in pregnant rats given MBuP on days 7-9 and days 10-12 at doses of 625 mg/kg and above and on days 13-15 at doses of 500 mg/kg and above. No evidence of teratogenicity was found when MBuP was given on days 10-12 of pregnancy. A significantly increased incidence of fetuses with external malformations was found after treatment with MBuP on days 7-9 and days 13-15 at doses of 625 and 750 mg/kg. A significantly increased incidence of fetuses with skeletal malformations was observed after treatment with MBuP on days 7-9 at doses of 500 mg/kg and above and on days 13-15 at doses of 625 mg/kg and above. Deformity of the cervical vertebrae was predominantly observed following treatment with MBuP on days 7-9. Cleft palate and fusion of the sternebrae were exclusively found following treatment with MBuP on days 13-15. It could be concluded that the manifestation of deviant development induced by MBuP varies with the developmental stage at the time of administration.

Developmental toxicity evaluation of mono-n-butyl phthalate in rats

Mono-n-butyl phthalate (MBuP) was evaluated for developmental toxicity in Wistar rats. Rats were given MBuP by gastric intubation at 0, 250, 500 or 625 mg/kg on days 7-15 of pregnancy. Significant decreases in the maternal body weight gains and food consumption during pregnancy were found at 500 and 625 mg/kg. Significant increase in the incidence of postimplantation loss per litter and decreases in the number of live fetuses per litter and fetal weight were also detected at 500 mg/kg and above. The incidence of fetuses with malformations in the 500 and 625 mg/kg groups was higher than that in the control group. Cleft palate, deformity of the vertebral column and dilatation of the renal pelvis were frequently observed.

Developmental toxicity study in rats treated with the anticonvulsant, ralitoline

The developmental toxicity of the anticonvulsant compound, ralitoline, was investigated in Sprague-Dawley rats administered oral doses of 0, 15, 60, 120, 180, or 240 mg/kg on days 6 through 15 of gestation. An untreated control group and a vehicle control group pair-fed to the high dose group were included. Maternal and fetal parameters were evaluated on day 21 of gestation. Fetuses were examined for external, visceral, and skeletal malformations and variations. Maternal death occurred at 180 and 240 mg/kg. Dose-dependent decreases in body weight, food consumption, and water consumption were observed at 60 mg/kg and above. Body weight gain during treatment was similar in the pair-fed and 240 mg/kg groups. Dose-related CNS signs (hypoactivity, ataxia, prostration, and/or convulsions) were observed at 60 mg/kg and above. Decreased numbers of live fetuses and increased postimplantation loss were observed in a dose-related manner at 120, 180, and 240 mg/kg while no changes occurred in pair-fed controls. Fetal body weights and placental weights were decreased in pair-fed controls and in the 120, 180, and 240 mg/kg groups. The percent fetuses per litter, and the percent litters with external/visceral malformations, were significantly increased at 120, 180, and 240 mg/kg compared with vehicle and pair-fed controls. Dose-related increases in cardiovascular malformations, specifically of the aortic arch (interrupted, stenotic, extra vessel), were apparent at 120 mg/kg and above. The incidence of skeletal variations was increased at 120 mg/kg and above.(ABSTRACT TRUNCATED AT 250 WORDS)

Embryolethality of butyl benzyl phthalate during early pregnancy in rats

In our previous studies, butyl benzyl phthalate (BBP) was found to be embryolethal and teratogenic in rats. In order to extend these findings, the effects of BBP during early pregnancy on maternal parameters were examined. Pregnant rats were given dietary BBP at 2.0% on day 0 through the day of sacrifice, day 7, 9, or 11 of pregnancy. The number of corpora lutea and implantations and the incidence of preimplantation embryonic loss were comparable across all groups. The postimplantation embryonic loss on day 11 in the 2.0% BBP group was markedly higher than that in the control and pair-fed groups. Regardless of the day of sacrifice, the uterine and ovarian weights and plasma progesterone levels, except for the ovarian weight on day 7, in the 2.0% BBP groups were significantly lower than those in the control and pair-fed groups. These findings suggest that the postimplantation embryonic loss due to BBP during early pregnancy is mediated via the reduction in plasma progesterone levels, an impairment of luteal function.

Characterization of the developmental toxicity of di-n-butyl phthalate in rats

The objective of this study was to determine the characterization of the developmental toxicity of di-n-butyl phthalate (DBP) in rats. Pregnant rats were given DBP by gastric intubation at a dose of 0.75, 1.0 or 1.5 g/kg on days 7-9, 10-12 or 13-15 of pregnancy. Postimplantation loss was 100% for each period of dosing at 1.5 g/kg. A significant increase in the postimplantation loss was found in dams given DBP at doses of 0.75 and 1.0 g/kg regardless of the days of treatment. No evidence of teratogenicity was detected when DBP was given on days 10-12. Treatment on days 7-9 with DBP at doses of 0.75 and 1.0 g/kg caused a significant increase in the number of skeletal malformations such as deformity of the vertebral column in the cervical and thoracic regions and of the ribs, but neither external nor internal malformations. Treatment with DBP on days 13-15 at doses of 0.75 and 1.0 g/kg resulted in a significant increase in the incidence of fetuses with external and skeletal malformations such as cleft palate and fusion of the sternebrae. The frequency of malformations increased as the dose of DBP was increased. The highest incidence of malformed fetuses occurred after treatment with DBP on days 13-15. It could be concluded that susceptibility to the teratogenicity of DBP varies with the developmental stage at the time of administration.

Prenatal effects of technical hexachlorocyclohexane in mice

Technical hexachlorocyclohexane (5, 25, and 50 mg/kg/d) was orally administered to mice during the pre- and postimplantation period. While mice exposed to HCH during the preimplantation period did not show fetolethality, exposure during the postimplantation period showed dose-dependent effects on fetuses as evidenced by increase in percentage resorption, higher level of HCH residue, and decreased serum progesterone level. The absence of anomalies in fetal gross morphology and skeleton suggests technical HCH is nonteratogenic in mice.

Teratogenic phase specificity of butyl benzyl phthalate in rats

Pregnant rats were given butyl benzyl phthalate (BBP) by gastric intubation at a dose of 0.6, 0.75 or 1.0 g/kg on days 7-9, 10-12 or 13-15 of pregnancy. While treatment with BBP on days 7-9 or 13-15 at doses of 0.75 and 1.0 g/kg was significantly teratogenic, no evidence of teratogenicity was detected when BBP was given on days 10-12. The incidence of malformed fetuses was proportional to the dose of BBP. Treatment on days 7-9 with BBP at doses of 0.75 g/kg and above caused a significant increase in the number of skeletal malformations, such as fusion of the cervical vertebral arches and deformity of the thoracic vertebrae, but neither external nor internal malformations. Treatment on days 13-15 with two higher doses of BBP resulted in a significantly increased incidence of fetuses with external and skeletal malformations such as cleft palate and fusion of the sternebrae. The highest incidence of malformed fetuses occurred after treatment with BBP on days 13-15. It could be concluded that the susceptibility to the teratogenicity of BBP varies with the developmental stage at the time of administration.

Teratogenic evaluation of butyl benzyl phthalate in rats by gastric intubation

Pregnant rats were given butyl benzyl phthalate (BBP) by gastric intubation at a dose of 0, 0.5, 0.75 or 1.0 g/kg on days 7-15 of pregnancy. In the 0.5 g/kg group, food consumption during the administration period was significantly decreased, but no adverse effect on the embryo-fetus was detected. High maternal lethality and complete resorption of implanted embryos in all the surviving dams were observed in the 1.0 g/kg group. Increased embryo-fetal death and decreased fetal weight were found at a dose of 0.75 g/kg which also caused reductions in maternal body weight gain and food consumption. A significantly and markedly increased incidence of fetal malformations was also detected in the 0.75 g/kg group. Cleft palate, fusion of the sternebrae and dilatation of the renal pelvis were mostly observed.